TriangleHEALTH PROFESSIONAL · SOURCE READING
Other genomic alterations
Source: Childhood Cancer Genomics (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 30, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
As an alternative to BRAF activation or NF1 loss, other primary oncogenic driver alterations along the MAPK signaling pathway have been observed in pilocytic astrocytomas and other pediatric-type gliomas. These include oncogenic variants and/or fusions involving FGFR1, FGFR2, PTPN11, RAF1, NTRK2, and others.[4,7,22]
Low-grade gliomas with rearrangements in the MYB family of transcription factors [2,3,7] have been classified as a separate entity: diffuse astrocytoma, MYB- or MYBL1-altered, WHO grade 1.[1] Prognosis is generally favorable for patients with these tumors, particularly when a gross-total resection or near-total resection is obtained at the time of surgery.[23]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice